Aim: People with primary brain tumour (PBT) report high levels of fatigue. This systematic review aimed to synthesise the evidence on use and effectiveness of non-pharmacological interventions for fatigue in people with PBT.
Methods: This review was prospectively registered with PROSPERO. PsycInfo, Medline, Scopus, CINAHL, and Web of Science databases were searched in August 2023 using terms related to fatigue, PBT, non-pharmacological approaches, and interventions/treatment. Randomised controlled trials (RCT) and non-randomised studies were included. A narrative synthesis approach was employed to analyse extracted information. The Cochrane Risk of Bias (RoB-2) and Risk of Bias in Non-randomised Studies of Interventions (ROBINS-I) tools were applied.
Results: We identified 18 articles; 10 RCTs, 4 single-arm studies, 3 case studies, and 1 quasi-experimental study. Interventions included exercise-based interventions (n=10), cognitive rehabilitation (n=3), education/self-help (n=2), psychological (n=1), neuromuscular stimulation (n=1), and nursing (n=1). Eight were feasibility/pilot studies and 11 had small sample sizes (N<30). Six studies (3/10 RCTs) reported a statistically significant reduction in fatigue post-intervention. Studies, including those with positive results, commonly reported fatigue as a secondary outcome, had high attrition, and/or were uncontrolled. Regarding risk of bias for RCTs, 2 studies had a low risk of bias, 6 ‘some concerns’, and 2 a high risk. For non-randomised studies, 4 had a moderate risk, and 1 a high risk of bias.
Conclusions: Current evidence to suggest the effectiveness of non-pharmacological interventions for fatigue in people with PBT is limited and effective elements of these interventions were not identifiable. Mixed results, small sample sizes, and high attrition rates highlight the need for novel approaches when conducting non-pharmacological studies for fatigue in this population. Inherent challenges associated with research in this population necessitates alternative methodologies. Innovative trial designs such as platform trials, n-of-1 studies, stated-preference studies, and tailored interventions, should be considered for future trials.